£2.7M
Epidarex Capital and the University of Leeds led the Series A round to support the development of next generation anticoagulants.
LT
LUNAC Therapeutics
LUNAC Therapeutics develops advanced anticoagulants targeting activated Factor XII.
£2.7MTotal raised
LUNAC Therapeutics is a drug discovery company developing next generation anticoagulants designed to minimise bleeding risk. The firm emerged as a spin out from the University of Leeds.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Current assets
Members only
Cash, assets and headcount from LUNAC Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Helen Philippou
Scientific Founder
Helen is the chief executive officer of ClotProtect Therapeutics and co-founder director of Lunac Therapeutics. She also serves as chair of the International Society of Fibrinolysis and Proteolysis and professor of translational medicine at the University of Leeds.
LinkedInRF
Richard Foster